Abstract
Current protocols for differentiating human induced pluripotent stem cells (hiPSCs) into cardiomyocytes (CMs) for cellular therapy still need improvement due to the occurrence of arrhythmias in preclinical trials, which limits their therapeutic application. This is mainly attributed to the insufficient maturation and electrophysiological heterogeneity of CMs obtained with current differen…